XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and Intangible Assets, Net
3 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net The Company evaluates goodwill for impairment on an annual basis and at an interim date, if indicators of potential impairment exist. The Company voluntarily changed its annual goodwill impairment testing date from October 1st to April 1st to align with a change in timing of the Company’s annual long-term planning process. Accordingly, management determined that the change in accounting principle is preferable under the circumstance. This change has been applied prospectively from April 1, 2022 as retrospective application is deemed impracticable due to the inability to objectively determine the assumptions and significant estimates used in earlier periods without the benefit of hindsight. This change was not material to the Company’s consolidated financial statements as it did not delay, accelerate, or avoid any potential goodwill impairment charge. The annual impairment testing performed as of April 1, 2022 did not indicate an impairment of goodwill.
Changes in the carrying amount of goodwill were as follows:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2022$3,923 $1,542 $2,453 $1,533 $9,451 
Foreign currency translation adjustments, net(33)— — (48)(81)
Other adjustments(3)— — (2)
Balance, June 30, 2022$3,887 $1,542 $2,453 $1,486 $9,368 
Information regarding intangible assets is as follows:
 June 30, 2022March 31, 2022
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships12$2,747 $(1,695)$1,052 $2,777 $(1,691)$1,086 
Service agreements91,078 (584)494 1,085 (573)512 
Trademarks and trade names11802 (397)405 819 (386)433 
Technology1127 (118)128 (116)12 
Other9188 (172)16 187 (171)16 
Total $4,942 $(2,966)$1,976 $4,996 $(2,937)$2,059 
Amortization expense of intangible assets was $56 million and $98 million during the three months ended June 30, 2022 and 2021, respectively. Estimated amortization expense of these assets is as follows: $166 million, $211 million, $206 million, $174 million, and $168 million for the remainder of fiscal 2023 and each of the succeeding years through fiscal 2027, respectively, and $1.1 billion thereafter. All intangible assets were subject to amortization as of June 30, 2022 and March 31, 2022. Amortization of intangible assets of the E.U. disposal group classified as held for sale ceased in the second quarter of fiscal 2022.